Engine Capital Management’s Harvard Bioscience HBIO Stock Holding History

Engine Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,022	Closed	-$280K	–	34
2020 Q2	$280K	Sell	9,022 -373,869	-98%	-$10.1M	0.18%	32
2020 Q1	$10.8M	Buy	382,891 +61,942	+19%	+$1.68M	5.61%	9
2019 Q4	$9.79M	Sell	320,949 -33,336	-9%	-$959K	3.82%	8
2019 Q3	$10.5M	Buy	354,285 +167,480	+90%	+$4.16M	4.92%	7
2019 Q2	$3.74M	Buy	+186,805	New	+$5.47M	1.79%	20

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Engine Capital Management's HBIO Position: Q3 2020 in Review

Engine Capital Management sold out of Harvard Bioscience (HBIO) in Q3 2020, closing a stake of 9,022 shares — an estimated $280K sold.

Engine Capital Management first reported a position in HBIO in Q2 2019 and held it in 5 quarters. The position peaked at $10.8M in Q1 2020. 85 funds tracked by Wall St. Rank hold HBIO as of Q3 2020.

Engine Capital Management reported no remaining Harvard Bioscience position as of Q3 2020 after selling out during the quarter.
Engine Capital Management sold 9,022 Harvard Bioscience shares in Q3 2020, an estimated $280K.
Engine Capital Management first reported a position in Harvard Bioscience in Q2 2019 and held it in 5 quarters.
Engine Capital Management's Harvard Bioscience position peaked at $10.8M in Q1 2020.
85 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2020.

Based on Engine Capital Management's 13F filing for Q3 2020, filed 17 Nov 2020.